drugset / Trial / NCT04515576
A Study of LY3493269 in Participants With Type 2 Diabetes
RandomizedParallel-groupDouble-blindBasic science
Summary
The main purpose of this study is to determine the side effects related to LY3493269 in participants with type 2 diabetes. Blood tests will be performed to check concentrations of LY3493269 in the bloodstream. Each enrolled participant will receive LY3493269, dulaglutide, or placebo. The study will last up to approximately 16 weeks for each participant and may include up to 11 visits.
Timeline
- Start
- 2020-08-25
- Primary completion
- 2021-03-09
- Completion
- 2021-03-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dulaglutide | Peptide | 1.5 mg | Subcutaneous |
| Subject | LY3493269 | Unknown | 0.3 mg | Subcutaneous |
| Subject | LY3493269 | Unknown | 1 mg | Subcutaneous |
| Subject | LY3493269 | Unknown | 3 mg | Subcutaneous |
| Subject | LY3493269 | Unknown | 5 mg | Subcutaneous |